CN107892712B - 小分子多肽及其用途 - Google Patents
小分子多肽及其用途 Download PDFInfo
- Publication number
- CN107892712B CN107892712B CN201711497614.5A CN201711497614A CN107892712B CN 107892712 B CN107892712 B CN 107892712B CN 201711497614 A CN201711497614 A CN 201711497614A CN 107892712 B CN107892712 B CN 107892712B
- Authority
- CN
- China
- Prior art keywords
- polypeptide
- small molecule
- application
- molecule polypeptide
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 36
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 36
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 36
- 150000003384 small molecules Chemical class 0.000 title claims abstract description 18
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 2
- 230000002141 anti-parasite Effects 0.000 abstract description 7
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 150000001413 amino acids Chemical group 0.000 description 7
- 239000011347 resin Substances 0.000 description 7
- 229920005989 resin Polymers 0.000 description 7
- 239000003096 antiparasitic agent Substances 0.000 description 5
- 244000045947 parasite Species 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 208000030852 Parasitic disease Diseases 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 2
- 229940124350 antibacterial drug Drugs 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000012136 culture method Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- CNKBMTKICGGSCQ-ACRUOGEOSA-N (2S)-2-[[(2S)-2-[[(2S)-2,6-diamino-1-oxohexyl]amino]-1-oxo-3-phenylpropyl]amino]-3-(4-hydroxyphenyl)propanoic acid Chemical compound C([C@H](NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=CC=C1 CNKBMTKICGGSCQ-ACRUOGEOSA-N 0.000 description 1
- JZTKZVJMSCONAK-INIZCTEOSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-hydroxypropanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CO)C(O)=O)C3=CC=CC=C3C2=C1 JZTKZVJMSCONAK-INIZCTEOSA-N 0.000 description 1
- RSWGJHLUYNHPMX-UHFFFAOYSA-N 1,4a-dimethyl-7-propan-2-yl-2,3,4,4b,5,6,10,10a-octahydrophenanthrene-1-carboxylic acid Chemical compound C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- FRBAHXABMQXSJQ-FXQIFTODSA-N Arg-Ser-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O FRBAHXABMQXSJQ-FXQIFTODSA-N 0.000 description 1
- QHAJMRDEWNAIBQ-FXQIFTODSA-N Asp-Arg-Asn Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=O QHAJMRDEWNAIBQ-FXQIFTODSA-N 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- UCMIKRLLIOVDRJ-XKBZYTNZSA-N Cys-Gln-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CS)N)O UCMIKRLLIOVDRJ-XKBZYTNZSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- JHPFPROFOAJRFN-IHRRRGAJSA-N Gln-Glu-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)N)O JHPFPROFOAJRFN-IHRRRGAJSA-N 0.000 description 1
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- OJFFAQFRCVPHNN-JYBASQMISA-N Ser-Thr-Trp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O OJFFAQFRCVPHNN-JYBASQMISA-N 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- YOSLMIPKOUAHKI-OLHMAJIHSA-N Thr-Asp-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O YOSLMIPKOUAHKI-OLHMAJIHSA-N 0.000 description 1
- 241000224526 Trichomonas Species 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- -1 benzotriazole-N, N, N ', N' -tetramethylurea hexafluorophosphate Chemical compound 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 239000002173 cutting fluid Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940089468 hydroxyethylpiperazine ethane sulfonic acid Drugs 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000010267 two-fold dilution method Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明公开了一种小分子多肽,小分子多肽的氨基酸序列如SEQ ID No.1所示。本发明还提供了小分子多肽的用途。本发明的多肽具有良好的抗寄生虫活性,同时具备抗菌活性,稳定性强,结构易于调控,具有很明显的应用潜力。
Description
技术领域
本发明涉及一种小分子多肽。更具体地说,本发明涉及一种具有抗寄生虫和抗菌活性的小分子多肽。
背景技术
寄生虫病作为一种常见疾病,影响了世界人民的健康。例如,疟疾在非洲、亚洲和拉丁美洲等热带和亚热带地区成为一个严重的社会问题,每年有大约两亿人感染疟疾,超过五十万人死亡。目前,有效作用于寄生虫疾病的药物不多,而耐药性却经常发生。因此,寻找新的寄生虫疾病药物极为迫切,特别地,寻找一种具有寄生虫活性同时兼具其它生物活性的药物具有重要的意义。
发明内容
本发明的一个目的是提供一种小分子多肽及其用途,该小分子多肽稳定性强,并具有具有良好的抗寄生虫和抗菌活性。
为了实现根据本发明的这些目的和其它优点,提供了一种小分子多肽,小分子多肽的氨基酸序列如SEQ ID No.1所示。
优选的是,所述的小分子多肽,所述小分子多肽的等电点为4.5。
本发明还提供了一种小分子多肽的用途,用于制备抗菌药物。
本发明还提供了一种小分子多肽的用途,用于制备抗寄生虫药物。
本发明至少包括以下有益效果:
1、本发明的多肽具有良好的抗寄生虫活性,同时具备抗菌活性。
2、本发明方法是一种小分子多肽,稳定性强,结构易于调控,具有很明显的应用潜力。
3、本发明小分子多肽与大分子多肽相比合成方法简便,易于大规模生产。
本发明的其它优点、目标和特征将部分通过下面的说明体现,部分还将通过对本发明的研究和实践而为本领域的技术人员所理解。
具体实施方式
下面结合实施例对本发明做进一步的详细说明,以令本领域技术人员参照说明书文字能够据以实施。
实施例1
一种小分子多肽,小分子多肽的氨基酸序列如SEQ ID No.1所示;
SEQ ID No.1:RSSTDDDRNKFYQEYVSTWCQT。
所述小分子多肽的等电点为4.5。
所述小分子多肽的的分子量为2729.88g/mol。
所述小分子多肽的制备方法:
选用氨基酸-王树脂作为载体(树脂),用二氯甲烷将树脂充分溶胀,加入第一个Fmoc-保护氨基酸,用二甲基甲酰胺清洗几遍,用适当浓度的DBLK,将Fmoc-保护基团脱出,之后用二甲基甲酰胺清洗数遍,洗去DBLK,称取适合的缩合剂苯并三氮唑-N,N,N',N'-四甲基脲六氟磷酸盐和活化剂甲基吗啉以及C端第二个Fmoc-保护氨基酸(Fmoc-Ser-OH)进行偶联,通过茚三酮检测法进行检测确保连接比较完全,用二甲基甲酰胺清洗几遍,洗去残留的各种残基,活化剂和缩合剂,依氨基酸序列进行偶联,将所有的氨基酸连接结束后,脱去最后的Fmoc-保护基团,用切割液裂解,去除树脂和氨基酸保护基团,得到小分子多肽的粗品,送质谱确认产品分子量2729.88g/mol符合理论值。
实施例2
一、实验方法
在灭菌试管中加入1mL浓度为1×106个/mL的菌液,加入1mg本发明所提供的小分子多肽,37℃培养24小时后,培养基收集起来用倍比稀释,稀释倍数为10倍和涂布培养法检测活菌数。
二、实验结果:
表1本发明所述小分子多肽的杀菌率(%)
细菌 | ATCC 6538 | ATCC 25922 | ATCC 10231 | ATCC 9372 |
杀菌率 | 99.8% | 99.9% | 99.3% | 99.5% |
由表1可知,本发明所提供的小分子多肽,对金黄色葡萄球菌(ATCC 6538)、大肠埃希氏菌(ATCC 25922)、白假丝酵母(ATCC 10231)、枯草芽孢杆菌黑色变种(ATCC 9372)都具有很强的杀菌性,其杀菌率达99%以上。可见,本发明的小分子多肽可用于制备抗菌药物。
实施例3
采用荧光细胞分类分析(FACS)定量红细胞的寄生虫培养法来评估本发明产品的抗寄生虫活性。将实施例1得到的多肽溶解在1ml DMSO中,然后用由25mmol/L 4-羟乙基哌嗪乙磺酸缓冲液,32mmol/L NaHCO3和10%人血浆配成的RPMI 1640细胞培养介质稀释200倍。样品溶液随后依次用2倍稀释的方法配成11种不同浓度,将1ml,2×106/ml的寄生虫加入溶液中,在37℃放于5%CO2培养箱中培养48h。加入1ml 3%二脒基苯基吲哚溶液,再培养18h,用荧光细胞分类分析仪测定红细胞数,可以得出不同浓度样品对寄生虫的抑制率,计算出IC50值。
表2多肽对寄生虫的半数有效浓度(IC50)
寄生虫 | 疟原虫 | 毛滴虫 |
IC<sub>50</sub>(umol/mL) | 0.2±1.0 | 0.3±1.0 |
从实施例3的结果可以看出,本发明的多肽经抗寄生虫实验表明,该化合物具有强的抗寄生虫活性。可见,本发明的小分子多肽可用于制备抗寄生虫药物。
尽管本发明的实施方案已公开如上,但其并不仅仅限于说明书和实施方式中所列运用,它完全可以被适用于各种适合本发明的领域,对于熟悉本领域的人员而言,可容易地实现另外的修改,因此在不背离权利要求及等同范围所限定的一般概念下,本发明并不限于特定的细节和这里示出与描述的实施例。
SEQUENCE LISTING
<110> 广西中医药大学
<120> 小分子多肽及其用途
<130> application
<160> 1
<170> PatentIn version 3.5
<210> 1
<211> 22
<212> PRT
<213> 多肽
<400> 1
Arg Ser Ser Thr Asp Asp Asp Arg Asn Lys Phe Tyr Gln Glu Tyr Val
1 5 10 15
Ser Thr Trp Cys Gln Thr
20
Claims (2)
1.一种小分子多肽,其特征在于,小分子多肽的氨基酸序列如SEQ ID No.1所示。
2.如权利要求1所述的小分子多肽,其特征在于,所述小分子多肽的等电点为4.5。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711497614.5A CN107892712B (zh) | 2017-12-29 | 2017-12-29 | 小分子多肽及其用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711497614.5A CN107892712B (zh) | 2017-12-29 | 2017-12-29 | 小分子多肽及其用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107892712A CN107892712A (zh) | 2018-04-10 |
CN107892712B true CN107892712B (zh) | 2020-06-30 |
Family
ID=61808926
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711497614.5A Active CN107892712B (zh) | 2017-12-29 | 2017-12-29 | 小分子多肽及其用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107892712B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102079782A (zh) * | 2010-12-03 | 2011-06-01 | 厦门大学 | 一种杀灭刺激隐核虫的抗菌肽及其制备方法与应用 |
CN102382186A (zh) * | 2011-09-29 | 2012-03-21 | 东北农业大学 | 衍生自线性鸡β-防御素4(RL38)的抗菌肽GLI23及其制备方法 |
CN104004100A (zh) * | 2014-06-13 | 2014-08-27 | 山西农业大学 | 猪抗菌肽NK-lysin融合蛋白及其编码基因与应用 |
CN104904750A (zh) * | 2015-04-21 | 2015-09-16 | 漳州康创净化材料有限公司 | 一种生物抗菌剂、其制备方法及其应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070105754A1 (en) * | 2005-11-10 | 2007-05-10 | Pinto Da Silva Luis L | Pharmaceutical composition to prevent and treat epithelial wounds, immunomodulating pharmaceutical composition, pharmaceutical composition, insecticide, insecticide composition insecticide use of lectin KM+ to treat cicatrizations, use of lectin KM+ to prepare immunomodulating medicament, use of lectin KM+ to prepare anti-bacterial medicament, use lectin KM+ to prpare anti-viral medicament, use of lectin KM+ to prepare anti-parasite medicament, use of lectin KM+ to prepare anti-fungal medicament, use of lectin KM+ to prepare anti-parasite medicament expression method, DNA vector, recombinant |
CN104327168B (zh) * | 2014-09-29 | 2017-11-14 | 广西中医药大学 | 一种小分子多肽及其应用 |
CN104292309B (zh) * | 2014-09-29 | 2017-04-12 | 广西中医药大学 | 一种小分子多肽 |
CN104327164B (zh) * | 2014-09-29 | 2017-06-13 | 广西中医药大学 | 一种合成多肽及其用途 |
CN104327165B (zh) * | 2014-09-29 | 2017-07-28 | 广西中医药大学 | 一种多肽分子及其应用 |
CN104292307B (zh) * | 2014-09-29 | 2017-07-28 | 广西中医药大学 | 一种多肽分子 |
-
2017
- 2017-12-29 CN CN201711497614.5A patent/CN107892712B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102079782A (zh) * | 2010-12-03 | 2011-06-01 | 厦门大学 | 一种杀灭刺激隐核虫的抗菌肽及其制备方法与应用 |
CN102382186A (zh) * | 2011-09-29 | 2012-03-21 | 东北农业大学 | 衍生自线性鸡β-防御素4(RL38)的抗菌肽GLI23及其制备方法 |
CN104004100A (zh) * | 2014-06-13 | 2014-08-27 | 山西农业大学 | 猪抗菌肽NK-lysin融合蛋白及其编码基因与应用 |
CN104904750A (zh) * | 2015-04-21 | 2015-09-16 | 漳州康创净化材料有限公司 | 一种生物抗菌剂、其制备方法及其应用 |
Non-Patent Citations (1)
Title |
---|
小分子抗菌肽的虚拟组合设计、筛选与效应研究;王远强;《中国博士学位论文全文数据库 基础科学辑》;20121115(第11期);第3页,1.3抗菌肽发展历史,第4-5页,1.5抗菌肽构效关系及结构改造,附表S1-S3 * |
Also Published As
Publication number | Publication date |
---|---|
CN107892712A (zh) | 2018-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20190336568A1 (en) | Antimicobial peptides for inhibiting drug-resistant bacteria and uses thereof | |
CN105777889B (zh) | 一种杂合α螺旋型猪源抗菌肽及其制备方法和应用 | |
CN114057835B (zh) | 一种抗菌肽类似物及其制备方法与应用 | |
CN108276485A (zh) | 能抑制和杀灭革兰氏阴性菌的抗菌肽hv2及制备方法 | |
CN106496305B (zh) | 一组广谱高效的抗菌肽及其应用 | |
CN104774250B (zh) | 一种抗菌功能多肽及其制备方法和应用 | |
CN113121666B (zh) | 抗菌肽Scybaumancin105-127及其应用 | |
CN107892712B (zh) | 小分子多肽及其用途 | |
CN110776560B (zh) | 一种黑鲷抗菌肽AS-hepc3(48-56)及其应用 | |
CN107987133B (zh) | 小分子多肽及其用途 | |
CN110982709B (zh) | 一种能够抑制柑橘黑点病菌生长的棘孢木霉菌及其应用 | |
CN108218962B (zh) | 小分子多肽及其用途 | |
US10738005B2 (en) | Aziridinyl containing compounds and methods of inactivating nucleic acid molecules using the same | |
CN113951284A (zh) | 一种抗菌抗病毒植物复方精油及其制备方法和用途 | |
He et al. | Discovery of cryptolepine derivatives as novel promising agents against phytopathogenic bacteria | |
CN111067897A (zh) | 一种抗真菌的组合物及其应用 | |
CN105777887A (zh) | 一种石斑鱼Epinecidin-1多肽及其应用 | |
CN116286466A (zh) | 一种拮抗烟草赤星病病原菌的菌株及其应用 | |
Gifardi et al. | Antibacterial activity of Sunda porcupine quill extract (Hystrix javanica) against Staphylococcus aureus | |
CN102250216A (zh) | 黑斑蛙抗微生物肽及其基因和应用 | |
CN113912680B (zh) | 具有高抗菌活性的抗菌肽及其应用 | |
CN107021999A (zh) | 一种抗念珠菌的多肽及其用途、抗念珠菌的药物 | |
CN112219865A (zh) | 牛至精油在防治植物源病菌中的应用 | |
CN111388379A (zh) | 一种食品级免洗洗手液及其制备方法 | |
CN113248570B (zh) | 一种抗菌肽ht11及其衍生物和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210824 Address after: 402460 No. 57, Lingfang Avenue, high tech Industrial Park, Rongchang District, Chongqing Patentee after: Anjeli (Chongqing) Biotechnology Co.,Ltd. Address before: 530213 No. 13 Wuhe Avenue, Qingxiu District, Nanning City, Guangxi Zhuang Autonomous Region Patentee before: Guangxi University of Chinese Medicine |
|
PP01 | Preservation of patent right | ||
PP01 | Preservation of patent right |
Effective date of registration: 20240218 Granted publication date: 20200630 |